2024年，涨幅TOP10的创新药企中位数为57.9%，最高涨幅132.6%； 而2025年这一赛道彻底"卷"了起来，涨幅前十药企的中位数大幅攀升至495.41%，最高涨幅更是飙至1824%，入围门槛 则是315.29%——换句话说，股价不翻3倍，难以跻身前十大牛股行列。 | 2025年生物医药公司股价年涨幅TOP10 | | | | 2 2 百 1 元 | | --- | --- | --- | --- | --- | | 代理 | 名称 | 起始价/港元 | 收盘价(12/31)/港元 | 年初至今涨幅% | | 01228.HK | 北海康成-B | 0.13 | 2.56 | 1824.81 | | 02197.HK | 三叶草生物-B | 0.24 | 2.34 | 870.95 | | 02617.HK | 药捷安康-B | 13.2 | 114.9 | 773.76 | | 02142.HK | 和铂医药-B | 1.86 | 12.16 | 553.76 | | 02575.HK | 轩竹生物-B | 11.6 | 70.5 | 507.76 | | 06996.HK | 德琪医药-B | 0 ...

创新药板块迎来久违的大牛市，牛股的准入门槛也随之大幅抬高。 2024年，涨幅TOP10的创新药企中位数为57.9%，最高涨幅132.6%； 而2025年这一赛道彻底"卷"了起来，涨幅前十药企的中位数大幅攀升至495.41%，最高涨幅更是飙至1824%，入围门槛 则是315.29%——换句话说，股价不翻3倍，难以跻身前十大牛股行列。 | 代码 | 名称 | 起始价/港元 | 收盘价(12/31)/港元 | 年初至今涨幅% | | --- | --- | --- | --- | --- | | 01228.HK | 北海康成-B | 0.13 | 2.56 | 1824.81 | | 02197.HK | 三叶草生物-B | 0.24 | 2.34 | 870.95 | | 02617.HK | 药捷安康-B | 13.2 | 114.9 | 773.76 | | 02142.HK | 和铂医药-B | 1.86 | 12.16 | 553.76 | | 02575.HK | 轩竹生物-B | 11.6 | 70.5 | 507.76 | | 06996.HK | 德琪医药-B | 0.65 | 3.79 | 4 ...

轩竹生物-B(02575)发布公告，李嘉逵博士辞任本公司执行董事及总经理，以投放更多时间于其他业务 承担。 为确保企业管治及董事会运作顺利过渡，李博士承诺会继续忠实及勤勉尽责地履行执行董事职责。辞任 仅于本公司股东大会委任新执行董事加入董事会后生效。 ...

为确保企业管治及董事会运作顺利过渡，李博士承诺会继续忠实及勤勉尽责地履行执行董事职责。辞任 仅于本公司股东大会委任新执行董事加入董事会后生效。 智通财经APP讯，轩竹生物-B(02575)发布公告，李嘉逵博士辞任本公司执行董事及总经理，以投放更多 时间于其他业务承担。 ...

格隆汇1月2日丨轩竹生物-B(02575.HK)宣布，李嘉逵辞任公司执行董事及总经理，以投放更多时间于其 他业务承担。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：2575） 執行董事兼總經理辭任 董 事 會 謹 此 向 李 博 士 為 本 公 司 作 出 之 寶 貴 貢 獻 致 以 衷 心 感 謝。 承董事會命 軒 竹 生 物 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈 李 嘉 逵 博 士（「李博士」）辭 任 本 公 司 執 行 董 事 及 總 經 理，以 投 放 更 多 時 間 於 其 他 業 務 承 擔（「辭 任」）。 李博士確認(i)彼 與 董 事 會 並 無 任 何 意 見 分 歧；及(ii)並無有關辭任之其他事宜 須 提 請 聯 交 所 及 本 ...

Core Viewpoint - The "Technology Empowerment · Capital Breakthrough" sharing conference revealed the list of outstanding companies, highlighting the recognition of exceptional performance in the IPO sector [1] Group 1: Company Recognition - XuanZhu Biotechnology - B (2575.HK) won the "Annual Outstanding Investment Value IPO" award at the "Golden Grid Award" annual selection, acknowledging its strong performance in core business and significant growth potential in its industry [1]

Core Viewpoint - The "Annual Outstanding Investment Value IPO" awards recognize new listed companies that excel in core business, performance growth, and shareholder value creation, highlighting their significant growth potential and competitive advantages in their respective industries [4]. Group 1: Award Recipients - Eight companies received the "Annual Outstanding Investment Value IPO" award, including Different Group (06090.HK), Cao Cao Travel (02643.HK), Dipo Technology (01384.HK), Geek+ (02590.HK), Leshu (02698.HK), Tudatong (02665.HK), Xuan Bamboo Biotechnology-B (02575.HK), and Yingshi Innovation (688775.SH) [1]. - The ranking of the award recipients is not in any particular order and is based on the first letter of the company names [1]. Group 2: Evaluation Criteria - The evaluation for the awards was conducted through quantitative data analysis and an expert review panel [4]. - The awards aim to create a reference value for listed companies and unicorn companies within the investment community, emphasizing a global perspective with a focus on China [4]. Group 3: Coverage of the Awards - The "Golden Award" listing company evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4].

Core Viewpoint - XuanZhu Biotech's stock price has surged significantly, reflecting strong investor confidence in its innovative capabilities, with a cumulative increase of 700% since its IPO as of December 11 [1] Group 1: Company Performance - XuanZhu Biotech has launched three innovative drugs in three years, demonstrating its efficient R&D conversion system [5] - The company has successfully commercialized three innovative drugs in the "digestion + oncology" fields within a short span, showcasing its ability to address clinical pain points [5][6] - The stock price increase is attributed to the clinical value realization of its core products and the company's effective R&D strategy [5][7] Group 2: Product Details - Annelazole Sodium addresses two major clinical pain points in the PPI market: genetic adaptability and renal safety, achieving a significant reduction in efficacy differences among patients with different genetic types [6] - The drug has been included in the national medical insurance directory in its first year, filling a clinical demand gap [6] - The two oncology drugs, Pyrocil and Diroac, target unmet needs in HR+/HER2- breast cancer and ALK-positive NSCLC, respectively, enhancing the company's oncology pipeline [7][12] Group 3: Market Potential - The market for CDK4/6 inhibitors for breast cancer is projected to reach 9.8 billion yuan by 2030, with Pyrocil expected to penetrate the market rapidly due to its competitive clinical data [11] - The potential market for ALK inhibitors in NSCLC is estimated to reach 7.8 billion yuan by 2030, indicating a significant growth opportunity for Diroac [13] - The innovative drugs' clinical data support a shift in the industry valuation focus from pipeline thickness to individual product value density, positioning XuanZhu Biotech as a potential leader in niche markets [15]

Group 1: 52-Week Highs - A total of 44 stocks reached their 52-week highs as of December 12, with notable performers including Yuanmei Optoelectronics (08311) at 105.56%, Jinglian Group (01751) at 25.54%, and Xuan Bamboo Biotechnology - B (02575) at 23.60% [1] - The closing prices and peak prices for the top three stocks are as follows: Yuanmei Optoelectronics closed at 0.154 with a peak of 0.185, Jinglian Group closed at 1.850 with a peak of 2.310, and Xuan Bamboo Biotechnology - B closed at 82.950 with a peak of 96.900 [1] Group 2: 52-Week Lows - The report also highlighted stocks that reached their 52-week lows, with notable declines including Times China Holdings (01233) at -13.79%, Cornerstone Holdings (01592) at -11.36%, and HMVOD Video (08103) at -9.09% [2] - The closing prices and lowest prices for the top three declining stocks are as follows: Times China Holdings closed at 0.106 with a low of 0.100, Cornerstone Holdings closed at 0.198 with a low of 0.195, and HMVOD Video closed at 0.129 with a low of 0.120 [2]